122 related articles for article (PubMed ID: 9510503)
1. Significance of water solubility in the gastrointestinal absorption of trans-bis(n-valerato)(1R,2R-cyclohexanediamine)(oxalato)platinum(IV), an orally active antitumor platinum complex, and its analogs.
Kizu R; Nakanishi T; Yamamoto S; Hayakawa K; Matsuzawa A; Eriguchi M; Takeda Y; Akiyama N; Kidani Y
Anticancer Drugs; 1998 Feb; 9(2):167-74. PubMed ID: 9510503
[TBL] [Abstract][Full Text] [Related]
2. A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV).
Kizu R; Nakanishi T; Hayakawa K; Matsuzawa A; Eriguchi M; Takeda Y; Akiyama N; Tashiro T; Kidani Y
Cancer Chemother Pharmacol; 1999; 43(2):97-105. PubMed ID: 9923814
[TBL] [Abstract][Full Text] [Related]
3. An orally active antitumor cyclohexanediamine-Pt(IV) complex: trans,cis,cis-bis(n-valerato)(oxalato)(1R,2R-cyclohexane diamine)Pt(IV).
Kizu R; Nakanishi T; Miyazaki M; Tashiro T; Noji M; Matsuzawa A; Eriguchi M; Takeda Y; Akiyama N; Kidani Y
Anticancer Drugs; 1996 May; 7(3):248-56. PubMed ID: 8791997
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of a new lipophilic platinum compound, trans-bis(n-valerato)(1R,2R-cyclohexanediamine)(oxalato)platinum(IV), in mice.
Saegusa Y; Eriguchi M; Kidani Y; Matsuzawa A; Takeda Y
Anticancer Res; 2001; 21(1A):245-52. PubMed ID: 11299742
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of platinum(IV) and platinum(II) complexes containing 1R,2R-cyclohexanediamine as a ligand.
Yamashita T; Hirose J; Noji M; Saito R; Tomida H; Kidani Y
Biol Pharm Bull; 1993 Oct; 16(10):1014-8. PubMed ID: 8287030
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits.
Kizu R; Higashi S; Kidani Y; Miyazaki M
Cancer Chemother Pharmacol; 1993; 31(6):475-80. PubMed ID: 8453687
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, structure and antitumor activity of a new water-soluble platinum complex, (1R,2R-cyclohexanediamine-N,N')[2-hydroxy-4-oxo-2-pentenoato(2-)-O2] platinum(II).
Kawai H; Kitano Y; Mutoh M; Hata G
Chem Pharm Bull (Tokyo); 1993 Feb; 41(2):357-61. PubMed ID: 8500201
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
[TBL] [Abstract][Full Text] [Related]
9. Rectal absorption of [Bis (acetato) ammine dichloro (cyclohexylamine) platinum(IV)] (BMS-182751), a new anti-tumor agent, in rats.
Tanaka M; Kuwahara E; Shimizu T; Chikazawa H; Hisada S; Takahashi N
Biol Pharm Bull; 1999 May; 22(5):521-6. PubMed ID: 10375175
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structure and antitumor activity of a water-soluble platinum complex, (1R,3R,4R,5R)-(-)-quinato(1R,2R-cyclohexanediamine)platinum (II).
Hata G; Kitano Y; Kaneko T; Kawai H; Mutoh M
Chem Pharm Bull (Tokyo); 1992 Jun; 40(6):1604-5. PubMed ID: 1394681
[TBL] [Abstract][Full Text] [Related]
11. In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum (II) suspended in lipiodol.
Kishimoto S; Miyazawa K; Fukushima S; Takeuchi Y
Jpn J Cancer Res; 2000 Jan; 91(1):99-104. PubMed ID: 10744050
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
[TBL] [Abstract][Full Text] [Related]
13. In vitro cytotoxicity of cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) suspended in lipiodol in rat hepatoma AH-109A cells and human tumor cell lines.
Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
Biol Pharm Bull; 2000 Apr; 23(4):487-91. PubMed ID: 10784433
[TBL] [Abstract][Full Text] [Related]
14. In vitro release of SM-11355, cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) suspended in lipiodol.
Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
Biol Pharm Bull; 2000 May; 23(5):637-40. PubMed ID: 10823679
[TBL] [Abstract][Full Text] [Related]
15. Kinetic study of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of all-trans-retinoic acid in Sprague-Dawley rats after oral or intravenous administration.
Lin HS; Chan SY; Low KS; Shoon ML; Ho PC
J Pharm Sci; 2000 Feb; 89(2):260-7. PubMed ID: 10688755
[TBL] [Abstract][Full Text] [Related]
16. Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2).
Macias RI; El-Mir MY; Monte MJ; Serrano MA; Garcia MJ; Marin JJ
J Control Release; 1999 Feb; 57(2):161-9. PubMed ID: 9971896
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
[TBL] [Abstract][Full Text] [Related]
18. [Comparative studies of antitumor activities of oxalate (1R, 2R-cyclohexanediammine) platinum (II) and cis-dichlorodiammine-platinum (II) using ovarian cancer transplanted into nude mice].
Suzumori K; Yasui Y; Asai H; Yagami Y
Gan To Kagaku Ryoho; 1986 Feb; 13(2):280-5. PubMed ID: 3947107
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV).
Sova P; Mistr A; Kroutil A; Semerád M; Chlubnová H; Hrusková V; Chládková J; Chládek J
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1247-56. PubMed ID: 20697713
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
